1. Home
  2. BDJ vs ABCL Comparison

BDJ vs ABCL Comparison

Compare BDJ & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Enhanced Equity Dividend Trust

BDJ

Blackrock Enhanced Equity Dividend Trust

HOLD

Current Price

$9.76

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$6.93

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDJ
ABCL
Founded
2005
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BDJ
ABCL
Price
$9.76
$6.93
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.40
AVG Volume (30 Days)
422.9K
4.6M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
8.85%
N/A
EPS Growth
N/A
10.91
EPS
N/A
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
160.56
52 Week Low
$8.42
$2.75
52 Week High
$9.86
$8.44

Technical Indicators

Market Signals
Indicator
BDJ
ABCL
Relative Strength Index (RSI) 59.82 56.61
Support Level $9.05 $3.40
Resistance Level N/A $6.79
Average True Range (ATR) 0.09 0.44
MACD 0.00 0.05
Stochastic Oscillator 70.97 96.53

Price Performance

Historical Comparison
BDJ
ABCL

About BDJ Blackrock Enhanced Equity Dividend Trust

BlackRock Enhanced Equity Dividend Trust is a closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option to enhance distributions to its shareholders.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: